Press Releases argenx SE

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 16:55:00 10/04/2026 BST			5-day change	1st Jan Change
682.00 ^EUR	+0.80%		+5.38%	-4.85%

04-07	European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading	MT
04-02	Oppenheimer Adjusts Price Target on Argenx to $1,014 From $1,060, Maintains Outperform Rating	MT

Press Releases

03-20	Argenx announces Annual General Meeting of Shareholders on May 6, 2026	GL
03-19	Argenx : argenx announces Annual General Meeting of Shareholders on May 6, 2026	PU
03-06	Argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline	GL
02-26	Argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update	GL
02-26	Argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update	AQ
02-26	Argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis	GL
02-23	Argenx to Present at TD Cowen 46th Annual Healthcare Conference	GL
02-19	Argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026	GL
02-19	Argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026	AQ
01-13	Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	GL
01-13	Argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG	AQ
01-12	Argenx Highlights 2026 Strategic Priorities	GL
01-12	Argenx Highlights 2026 Strategic Priorities	AQ
01-06	Argenx to Present at 44th Annual J.P. Morgan Healthcare Conference	GL
01-05	Argenx Announces Leadership Transition Marking Next Evolution of Growth	GL
12-15	Argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease	GL
12-15	Argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease	AQ
11-18	Argenx Announces Results of Extraordinary General Meeting of Shareholders	GL
11-06	Argenx : FMR LLC - argenx SE - Breda	PU
11-05	/C O R R E C T I O N from source -- argenx Canada Inc./	AQ
30/10/25	Argenx : argenx Reports Third Quarter 2025 Financial Results and Provides Business Update	PU
30/10/25	Argenx : argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	PU
30/10/25	Argenx Reports Third Quarter 2025 Financial Results and Provides Business Update	GL
29/10/25	Argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients	GL
23/10/25	Argenx : argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025	PU